Genmab (GMAB) has released an update.
Genmab A/S, the Copenhagen-based biotech firm, has awarded 23,954 restricted stock units and 13,915 warrants to its employees, with the units vesting after three years and the warrants exercisable at DKK 1,597.50. These incentives, which aim to retain and motivate staff, align with the company’s vision to transform patient lives through innovative antibody medicines. The grants are part of Genmab’s broader compensation strategy, detailed on the company’s investor relations website.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
